Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is being done to answer the following question:
Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Full description
This study is being conducted in order to find out if this approach is as good as the usual approach in controlling the cancer and has fewer side effects and better quality of life. The usual approach for patients who are not in a study is treatment which includes radiotherapy to the tumour and to both sides of the neck to decrease the risk of spread or recurrence of the cancer
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with pathologically proven diagnosis of lateralized OPC (tonsil, tongue base, soft palate, or pharyngeal wall) not involving or crossing midline.
HPV positive or negative (by p16 immunohistochemistry).
Clinical stage T1-3 M0 (UICC/AJCC TNM 8th Edition). Nodal involvement may include no nodes or single or multiple ipsilateral lymph nodes (largest ≤6cm in maximum diameter)
Radiological investigations within 8 weeks of registration:
Planned definitive RT or CRT with bilateral neck RT (patients planned for unilateral neck RT are excluded).
Intent to deliver concurrent chemotherapy or not must be known at the time of randomization. As this is a pragmatic trial, even patients who are not candidates for systemic therapy will be eligible for participation.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Willing to complete the quality of life and/or health utility questionnaire, if sufficiently fluent in available language(s).
Informed consent prior to registration
Accessible for treatment and follow-up.
Commencement of definitive RT within 28 days (+ 14 days) of randomization.
Injection procedure for lymphatic mapping may be performed in the nuclear medicine, ambulatory clinic, or operating room setting
Women/men of childbearing potential must have agreed to use a highly effective contraceptive method
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Patient must consent to provision of, and investigator(s) must confirm location and commitment to obtain a representation of formalin fixed paraffin block of non-cytology tumour tissue in order that the specific correlative marker assays
Exclusion criteria
T1-T2 cancers isolated to the tonsil fossa (i.e. without any soft palate, tongue base, posterior pharyngeal wall or posterior tonsil pillar involvement) with no involved lymph nodes or with a single ipsilateral node < 3 cm without extranodal extension.
Tonsil or tongue base primary cancer who have previously undergone diagnostic palatine or lingual tonsillectomy with either complete excision or with no clinically apparent residual disease
Previous head and neck cancer or multiple synchronous primary head and neck cancers
Previous induction or neo-adjuvant chemotherapy.
Previous radiation therapy to the head and neck or comprehensive neck dissection of at least 3 levels on either side (due to potential for disrupted lymphatic channels and drainage pathways). Patients who have had excisional biopsies of involved lymph nodes are eligible
Radiotracer allergy
Severe, active co-morbidity including any of the following:
Primary purpose
Allocation
Interventional model
Masking
510 participants in 2 patient groups
Loading...
Central trial contact
Wendy Parulekar
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal